JNCE Key Statistics, Chart & Performance
The current stock price of JNCE is 1.88 USD. In the past month the price increased by 0.53%. In the past year, price decreased by -65.76%.
JNCE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to JNCE. When comparing the yearly performance of all stocks, JNCE turns out to be only a medium performer in the overall market: it outperformed 50.11% of all stocks.
JNCE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JNCE. While JNCE seems to be doing ok healthwise, there are quite some concerns on its profitability.
JNCE Financial Highlights
Over the last trailing twelve months JNCE reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 46.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
JNCE Forecast & Estimates
13 analysts have analysed JNCE and the average price target is 1.65 USD. This implies a price decrease of -12.29% is expected in the next year compared to the current price of 1.88.
For the next year, analysts expect an EPS growth of -37.55% and a revenue growth -100% for JNCE
JNCE Ownership
About JNCE
Company Profile
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.
Company Info
JOUNCE THERAPEUTICS INC
780 Memorial Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Murray
Employees: 141
Phone: 18572593840.0
JOUNCE THERAPEUTICS INC / JNCE FAQ
What does JOUNCE THERAPEUTICS INC do?
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.
Can you provide the latest stock price for JOUNCE THERAPEUTICS INC?
The current stock price of JNCE is 1.88 USD. The price decreased by -2.59% in the last trading session.
What is the dividend status of JOUNCE THERAPEUTICS INC?
JNCE does not pay a dividend.
What is the ChartMill rating of JOUNCE THERAPEUTICS INC stock?
JNCE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does JOUNCE THERAPEUTICS INC belong to?
JOUNCE THERAPEUTICS INC (JNCE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for JOUNCE THERAPEUTICS INC?
The Revenue of JOUNCE THERAPEUTICS INC (JNCE) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is JOUNCE THERAPEUTICS INC worth?
JOUNCE THERAPEUTICS INC (JNCE) has a market capitalization of 98.95M USD. This makes JNCE a Micro Cap stock.